Custom service

Peptide Antigen Synthesis and Conjugation Services

From a sequence to an immunogen, with the epitope left intact.

Peptide length: 8–60 residues; longer on evaluationPurity: Crude, >70%, >95% and >98% HPLC optionsModifications: Phospho, acetyl, methyl, citrulline, biotin, FITC, cyclic, MAP dendrimers

A peptide antigen is a small synthesis project that decides the outcome of a large antibody campaign. The sequence determines which epitope the antibody will recognise; the coupling site determines whether the discriminating residues stay exposed; the carrier determines how strong the response will be. Errors made here surface months later, as an antibody that binds the carrier or the spacer instead of the target.

Synthesis is by Fmoc solid-phase chemistry at three purity grades: crude for screening panels, >70% HPLC-purified for assay development, and >98% with mass confirmation for immunogens and standards. Modified residues — phospho, acetyl, methyl, citrullinated, disulfide-cyclised — are routine, and MALDI-TOF or ESI-MS confirms the product before anything is conjugated.

Conjugation is selected against the structure. Carboxylate haptens couple through EDC/NHS; amines through glutaraldehyde or succinic anhydride linkers; thiols through maleimide for a defined single point of attachment; hydroxyls through periodate oxidation. Where the free form matters, a terminal cysteine or a 3–6 carbon spacer is engineered into the peptide so the coupling happens away from the epitope. Multiple antigen peptide (MAP) constructs are offered when a carrier-free immunogen is preferred.

This service is the front end of anti-peptide antibody campaigns, phospho-antibody projects and anti-hapten immunogens, and it stands alone when a laboratory needs a defined coating antigen for an existing assay.

It is not a substitute for recombinant antigen when the epitope is conformational — a peptide cannot present a discontinuous surface — and peptide length beyond about 60 residues usually argues for recombinant expression instead.

Every peptide is supplied with an HPLC trace and a mass spectrum. Conjugates additionally carry the measured hapten density, SDS-PAGE and, where the coupling consumes a detectable group, a confirmation of the remaining free epitope. Immunisation-grade material is verified before it leaves the facility.

Service Highlights

  • Structure-led coupling. The coupling chemistry and spacer are chosen against the molecule, so the immunodiscriminating region stays exposed.
  • Three purity grades. Crude, >70% and >98% HPLC, each with ESI-MS or MALDI-TOF confirmation.
  • Modified residues routine. Phospho, acetyl, methyl, citrulline, cyclic and stapled peptides, plus peptide nucleic acid conjugates.
  • Carrier matched to purpose. KLH for immunisation, BSA and OVA for screening and coating, so carrier-specific responses can be separated.
  • MAP constructs. Octameric or tetravalent lysine-core dendrimers as carrier-free immunogens for short epitopes.
  • Conjugation ratio reported. Hapten-to-carrier ratio measured by MALDI-TOF or TNBS assay, since density shifts the immune response.

How the work runs

  1. Sequence review

    The peptide is examined for modification sites, hydrophobicity and the region that must remain exposed, and the coupling strategy is agreed.

  2. Synthesis

    Fmoc SPPS at the agreed scale and purity grade, with HPLC purification and mass confirmation.

  3. Conjugation

    Carrier coupling through the selected chemistry, with the reaction optimised to the target hapten density.

  4. Characterisation

    Conjugation ratio measured, free peptide removed by dialysis or SEC, and the conjugate checked by SDS-PAGE.

  5. Quality control

    Purity, mass and conjugate composition documented for both the free peptide and the conjugate.

  6. Delivery

    Conjugate supplied ready for immunisation, with an aliquot of the free peptide for screening use.

Specifications & timeline

Peptide length
8–60 residues; longer on evaluation
Purity
Crude, >70%, >95% and >98% HPLC options
Modifications
Phospho, acetyl, methyl, citrulline, biotin, FITC, cyclic, MAP dendrimers
Carriers
KLH, BSA, OVA, BTG, thyroglobulin
Conjugation
EDC/NHS, glutaraldehyde, maleimide, periodate, click chemistry
Timeline
1–3 weeks from sequence to conjugate

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.